Edison Investment Research - Zovio (0BD) Update: Trading resilience underpins H1 gains

Report

Edison Investment Research

Update: Trading resilience underpins H1 gains

Progress was expected and achieved in H1, although trading was not without its challenges. With polymer input prices showing signs of easing and more stable FX cross-rates currently, we expect a solid profit performance over the remainder of the year.

07/09/2015 5 EN

Underlying

Zovio

Bridgepoint Educations is a provider of postsecondary education services through its academic institutions. Ashford University? offers associate's, bachelor's and master's degree programs online and is comprised of four colleges: the Forbes School of Business and Technology?, the College of Education, the College of Health, Human Services and Science and the College of Liberal Arts. University of the Rockiessm provides master's and doctoral degree programs in the social and behavioral sciences. Classes are presented in an online format, and students at University of the Rockies attend via the institution's accessible online platform, which is also available through its mobile applications.

See profile

US10807M1053 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the 200-day moving average. This level is roughly 2,817 on the S&P 500 and roughly 1,000 on the S&P 600 Small Cap index. Some consolidation or a mild pullback is possible in the near-term, which we believe would help alleviate current overbought readings and allow for a more orderly and meaningful move higher. This constructive outlook is supported by the themes highlighted below: â€¢ Internals are healthy. The S&P 500 advance/decline line is advancing to ne...

EUR 234.60

March 5, 2019 March 5, 2019 31 EN

Valens Research

UAFRS vs As Reported Weekly Highlights - 2018 10 10

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for TSN, EQC, and BPI.

October 10, 2018 October 10, 2018 8 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

Remain overweight Tech-heavy Nasdaq; Large-cap Financials on the cusp of a breakout The S&P 500's pattern of notching higher lows and higher highs since early April has continued, with the index managing to stay above 2,800 resistance for the last five trading sessions. As long as this uptrend remains intact the new resistance level to monitor is 2,873, the all-time high set in January. â€¢ Nasdaq remains leadership; XLF on the cusp of a breakout. The tech and biotech-heavy Nasdaq continues to lead the market higher. Remain overweight. On the back of rising interest rates and a recently ...

EUR 234.60

July 24, 2018 July 24, 2018 28 EN

The Pebble Group - Two distinct businesses in one

The Pebble Group’s AGM update confirms that trading is in line with FY24 expectations, with attractive opportunities for its two distinct businesses in the large, fragmented promotional products sector. Facilisgroup is a SaaS business, helping North American distributors to optimise their operations, with access to an approved supplier roster. Brand Addition services global brands’ needs for branded product for in-house and external programmes. The well-publicised dip in tech sector marketing spend was a key factor in Pebble’s Q423 outlook revision. Both segments are now well placed to benefit...

2h / 48m 2h / 48m 1 EN

Richard Williamson

Richard Williamson

MotorK - Strong pipeline and cash target reaffirmed

MotorK’s FY23 revenue growth was robust across most regions, with slow growth regions gaining momentum. Q124 revenue fell slightly year-on-year due to delayed delivery contracts, but these are expected to contribute to Q2 sales. Revenue quality improved, with software-as-a-service (SaaS) recurring revenue rising as a share of group revenue in FY23. M&A continues to play a pivotal role in unlocking opportunities across MotorK's markets, providing potential average contract value (ACV) expansion from customers migrating to the platform. While personnel investments for growth swung EBITDA to a lo...

4h / 34m 4h / 34m 1 EN

Sean Conroy

Sean Conroy

Newron Pharmaceuticals - Evenamide notches up another win (study 008A)

Newron Pharmaceuticals has shared positive top-line data for its evenamide programme from its potentially pivotal Phase II/III trial (study 008A) in patients with poorly managed schizophrenia on current antipsychotic therapy, but not considered treatment-resistant. The trial met its primary endpoint of improvement on the Positive and Negative Syndrome Scale (PANSS) score from baseline, and the key secondary endpoint of improvement on the Clinical Global Impression of Severity (CGI-S) scale. Statistical significance was met in both, consolidating the already strong results from the Phase II tri...

4h / 45m 4h / 45m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Trading resilience underpins H1 gains

Vermilion Compass: Weekly Equity Strategy

UAFRS vs As Reported Weekly Highlights - 2018 10 10

Vermilion Compass: Weekly Equity Strategy

The Pebble Group - Two distinct businesses in one

MotorK - Strong pipeline and cash target reaffirmed

Newron Pharmaceuticals - Evenamide notches up another win (study 008A)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe